[Form 4] USANA Health Sciences Inc Insider Trading Activity

Rhea-AI Filing Summary

Myron W. Wentz, a director and >10% owner of USANA Health Sciences (USNA), reported a sale of 145,000 shares of Common Stock. After the reported disposition, the filing shows beneficial ownership of 7,408,345 shares held indirectly through Gull Global Limited, an entity Dr. Wentz indirectly owns and controls. The filing also explains Gull Global Limited is owned 50% by Viron Company Limited and 50% by Myogen Limited, each ultimately controlled by Dr. Wentz. The disclosure is limited to the change in share count and the ownership chain; no option or derivative transactions are reported.

Positive

• Transparent indirect ownership disclosure identifying Gull Global Limited and its ownership chain
• Reporting of the disposition clarifies current beneficial ownership level after the transaction

Negative

• Insider disposition of 145,000 shares could be perceived negatively by some investors
• Filing lacks narrative on the economic reason for the sale beyond the transaction code

Insights

Securities Analyst

TL;DR: Insider sold a modest block while retaining a large indirect stake; disclosure is routine and informational.

The sale of 145,000 shares reduces the insider's direct record position but leaves an indirect stake of over 7.4 million shares, indicating continued substantial alignment with shareholders. The transaction code reported ("G") indicates disposition under a pre-existing plan or similar mechanism rather than an open-market timing decision, which lessens signaling risk. No derivative activity was disclosed, simplifying the ownership picture.

Corporate Governance Expert

TL;DR: Governance disclosure is clear about ownership structure but provides limited context on economic motive.

The filing appropriately identifies the indirect ownership chain through Gull Global Limited and the two intermediary companies, which supports transparency about control. However, the form does not include the reason for the disposition beyond the transaction code, so readers cannot assess whether the sale is for diversification, tax planning, or other purposes. From a governance perspective, continued large indirect ownership keeps founder incentives aligned with long-term value.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WENTZ MYRON W

(Last) (First) (Middle)

C/O STERLING FINANCIAL GROUP

4525 SOUTH WASATCH BLVD, SUITE 250

(Street)

SALT LAKE CITY UT 84124

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
USANA HEALTH SCIENCES INC [ USNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		G		145,000	D	$0	7,408,345	I	Shares owned of record by Gull Global Limited(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

WENTZ MYRON W

(Last) (First) (Middle)

C/O STERLING FINANCIAL GROUP

4525 SOUTH WASATCH BLVD, SUITE 250

(Street)

SALT LAKE CITY UT 84124

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

1. Name and Address of Reporting Person^*

Gull Global Ltd

(Last) (First) (Middle)

PO BOX N-4899, 2/F BAHAMAS FINANCIAL CTR

SHIRLEY & CHARLOTTE STREETS

(Street)

NASSAU C5 BH1-1000

(City) (State) (Zip)

Relationship of Reporting Person(s) to Issuer

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

Explanation of Responses:

1. The holder of record of the shares of Common Stock disposed of is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Gull Global Limited is directly owned 50% by Viron Company Limited and 50% by Myogen Limited, each of which is a company formed under the Commonwealth of the Bahamas and is wholly indirectly owned and controlled by Dr. Wentz.

	Myron W. Wentz /s/ Valarie A. Hing Name: Valarie A. Hing Title: Attorney-in-Fact	09/05/2025
	GULL GLOBAL LIMITED /s/ Valarie A. Hing Name: Valarie A. Hing Title: Attorney-in-Fact	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Myron W. Wentz report for USNA?

The filing reports a disposition of 145,000 shares of USANA Health Sciences common stock.

How many USNA shares does Myron W. Wentz beneficially own after the reported sale?

The filing shows 7,408,345 shares beneficially owned indirectly through Gull Global Limited following the transaction.

Through which entity does Dr. Wentz hold his USNA shares?

Shares are held of record by Gull Global Limited, which the filing states is indirectly owned and controlled by Dr. Wentz.

Did the Form 4 disclose any derivative securities for USNA?

No. No derivative securities or option transactions are reported in the filing.

What does the transaction code "G" indicate on this Form 4?

In this filing the transaction is labeled with code G, indicating a disposition pursuant to a previously established plan or similar arrangement as reported on the form.